# SolasCure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/solascure

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.solascure.com
- Total disclosed funding: $34M
- Latest round: Series B (Mar 27, 2023)
- Investors on record: 6

## About

Founded in 2017 and based in Cambridge, UK, SolasCure Limited also known as AURASE, is a biotechnology company developing wound care products for different chronic wounds. The company is a spin-off from BRAIN Biotech AG, a German biotech company that focuses on harnessing biological diversity to develop various innovative solutions. It was founded by its CEO Dr. Sam Bakri, along with Benjamin Newmark. Dr. Bakri also served as the CEO and co-founder of Kind Consumer, co-founder of AIDA Health, and as a Vice-Chairman of Gelmetix Healthcare. In August 2021, SolasCure Limited received its latest GBP 15 million Series A funding from a group of investors that includes BRAIN Biotech AG, Seneca Partners, and Bionova Capital.

The company develops Aurase®, a hydrogel containing an enzyme cloned from medical maggots that helps in the acceleration of wound cleaning for various chronic wounds. It aims to provide a solution to painful or inadequate debridement procedures such as surgical or autolytic debridement for setting that includes hospitals, nursing homes, or home care.

The company's revenue is generated by the sales of its therapeutic product for medical use.

The company will use the proceeds of its Series A funding for its wound cleaning product, Aurase®.

## Funding rounds

- Series B, Mar 27, 2023, $13M — Seneca Partners, B.R.A.I.N. Biotechnology Research and Information Network AG, Wealth Club, EVA Pharma
- Series A, Aug 9, 2021, $21M — Development Bank of Wales, Seneca Partners, B.R.A.I.N. Biotechnology Research and Information Network AG, Biovance Capital, EVA Pharma

## Investors

- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Series A
- Seneca Partners — Series A, Series B
- B.R.A.I.N. Biotechnology Research and Information Network AG — Series A, Series B
- Biovance Capital (https://capitalatlas.ai/funds/biovance-capital) — Series A
- EVA Pharma — Series A, Series B
- Wealth Club — Series B